ASX Release

Recce Pharmaceuticals
recce.com.au
ACN 124 849 065

The Companies Officer
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000

Cleansing notice under section 708A of the Corporations Act

On 1 December 2017, Recce Pharmaceuticals Limited **(ASX:RCE) (Company)** issued 620,347 fully paid ordinary shares in accordance with the terms of its Share Purchase and Convertible Security Agreement with The Australian Special Opportunity Fund, LP, which was announced to the market on 16 June 2017.

The Company gives this notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) and states the following:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
   a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
   b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Corporations Act.

For more information, please contact the undersigned on (+61) 2 8072 1400.

Alistair McKeough
Company Secretary

For further information please visit www.recce.com.au or contact:

Investor Relations
James Graham
Executive Director Recce Pharmaceuticals Ltd
Tel: +61 (02) 8075 4585

Media (Australia)
Andrew Geddes
CityPR
Tel: +61 (02) 9267 4511

Media (International)
Sue Charles/Gemma Harris
Instinctif Partners
Tel: +44 (0)20 7866 7860
E: recce@instinctif.com